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ABSTRACT
Purpose Raloxifene undergoes extensive glucuronidation in
the gastrointestinal (GI) tract and the liver. However, the impact of age on raloxifene disposition has never been studied.
The purpose of this paper is to determine glucuronidation and
Pharmacokinetics (PK) profiles of raloxifene in rats at different
ages.
Methods Raloxifene glucuronidation was characterized using S9 fractions prepared from different intestinal segments
and the liver of F344 rats at 4-, 11-, and 28-week. PK studies
were conducted to determine raloxifene oral bioavailability at
different ages. Raloxifene and its glucuronides were quantified
using LC-MS/MS.
Results Raloxifene-6-glucuronide and raloxifene-4′-glucuronide were detected as the major metabolites and the ratio of
these two glucuronides were different ranging from 2.1 to 4.9
folds in the ileum, jejunum, liver, and duodenum, and from
14.5 to 50 folds in the colon. The clearances in the duodenum
at 4-week for both two glucuronides were significantly lower
than those at the other two ages. PK studies showed that the
oral bioavailability of raloxifene is age dependent. The absolute oral bioavailability of raloxifene was 3.5-folds higher at 4week compared to that at 11-weeks. When raloxifene was
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administered through IV bolus, its half-life was 5.9 ± 1.16 h
and 3.7 ± 0.68 h at 11-and 4-week, respectively.
Conclusion These findings suggested that raloxifene metabolism in the duodenum was significantly slower at young age in
rats, which increased the oral bioavailability of raloxifene. At
11-week, enterohepatic recycling efficiency was higher than
that of 4-week. Raloxifene’s dose at different ages should be
carefully considered.

KEYWORDS Raloxifene . age . glucuronidation . PK
INTRODUCTION
Raloxifene (Fig. 1), a selective estrogen-receptor modulator, is
a mixed agonist and antagonist of estrogen receptor in different tissues (1). Several large and long-term clinical trials
showed that raloxifene increased bone mineral density and
reduced the risk of fracture in postmenopausal women (2–4).
Raloxifene was approved for the treatment and prevention of
osteoporosis in postmenopausal women using Evista as the
brand name. Other than the approved indication, raloxifene
was also found to be associated with reduced breast cancer in
postmenopausal women (5). In addition, raloxifene has been
continuously tested at different ages for the treatment of different types of diseases, such as middle-aged (18–50 years)
patients with schizophrenia (6), middle to old-age (40–
70 years) patients with refractory schizophrenia (7), and middle to old-age (55–86 years) patients with Castration-Resistant
Prostate Cancer (8). Raloxifene was also tested in pediatric
patients for the management of persistent pubertal gynecomastia (mean age 14.6 years) (9).
Raloxifene disposition has been well studied in adults or
using adult animals. After being taken orally, approximately
60% of raloxifene is rapidly absorbed in the gastrointestinal
tract. However, the absolute oral bioavailability of raloxifene
in human is only 2% (10) due to rapid metabolism in the
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Fig. 1 The structure of raloxifene
and its glucuronide metabolites
(raloxifene-6-glucuronide,
raloxifene-4′-glucuronide).
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gastrointestinal (GI) tract and the liver. The major metabolites
of raloxifene are raloxifene-6-glucuronide (Ral-6-G) and
raloxifene-4′-glucuronide (Ral-4′-G) (Fig. 1) mediated by different isoforms of glucuronosyltransferase (UGT/Ugt) including UGT1A1, 1A6, 1A8 and 1A10. Due to expression
variations of these UGT isoforms, the production of these
two major metabolites in the GI tract and the liver could be
different. For example, we found previously that Ral-4′-G is
the major metabolite in the intestine while both metabolites
are produced in the liver when incubated with human tissue
microsomes (11). In addition, raloxifene may undergo enterohepatic recycling through glucuronidation and de-glucuronidation, which enhances the impact of glucuronidation in the
GI tract and the liver on systemic exposure of raloxifene.
Currently, the doses used in most of the clinical trials regardless the age were 60 mg/day, which was suggested to be
used in postmenopausal women. However, raloxifene disposition could be age-dependent because expression of the involved metabolic enzymes (i.e., UGTs) is age-dependent.
Disposition variation could cause different drug exposure in
the plasma at different ages. The aim of the present study was
to determine the impact of age on raloxifene glucuronidation
and in vivo exposure using F344 rats.

MATERIALS AND METHODS
Chemicals and Reagents
Raloxifene hydrochloride (Ral), raloxifene-6-O-glucuronide
(Ral-6-G), and raloxifene-4′-O-glucuronide (Ral-4′-G) were
purchased from Toronto Research Chemicals (Toronto,
Canada, all compounds purity ≥99%). MgCl2,

Raloxifene-4’-glucuronide
(Ral-4’-G)

saccharolactone, alamethicin, formononetin, and UDPGA
were purchased from Sigma-Aldrich (St. Louis, MO), water,
methanol, and acetonitrile are LC-MS grade and purchased
from EMD (Gibbstown, NJ, USA). The primary polyclonal
antibodies against Ugt1a and β-actin was purchased from
(Cell Signaling Technology, Inc., MA). The polyvinylidene
fluoride membranes were obtained from Millipore
Corporation (MA, USA).
Animals
Female F344 rats were obtained from Harlan Laboratory
(Indianapolis, IN), and housed in the animal facility at the
University of Houston within an environmentally controlled
room (temperature, 23–27°C, humidity, 45–55%, and 12 h
dark-light cycle) with free access of water and a standard diet.
The animal study was approved by the IACUC at the
University of Houston.
Tissue Enzyme S9 Preparation
The liver and intestine S9 fractions were prepared from F344
rats aged 4, 11, and 28 weeks according to the protocol published by us previously (12, 13). Briefly, rats (n = 6) at 4 (80 ±
10 g), 11 (150 ± 10 g), or 28 (250 ± 10 g) weeks were fasted
overnight and sacrificed to collect the liver and intestine tissues. The fresh tissues were flushed with cold buffer to remove
the blood and luminal content, and then humorized followed
by centrifugation at 9000×g for 15 mins at 4°C to afford S9
fractions. The protein concentrations were measured
using the Pierce™ BCA Protein Assay Kit (Thermos
Scientific, USA).
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Glucuronidation Reaction

Data Calculation and Statistical Analysis

The glucuronidation reaction was carried out using a standard protocol described in our previous publication (14).
Briefly, tissue S9 fractions, MgCl2 (5 mM), saccharolactone
(4.4 mM), alamethicin (0.022 mg/ml), and UDPGA
(3.5 mM) were mixed in a 50 mM potassium phosphate buffer
(pH 79.4, total volume 170 μL). Then raloxifene (Final concentration 0.125, 0.25, 0.5, 1, 2.5, 5, 10, 12.5, 25 μM) was
incubated in the above mixture for 60 min at 37°C. The
reaction was then terminated by adding 100 μL acetonitrile
solution containing 0.6% formic acid and 100 nM formononetin as the internal standard (I.S.). Samples were then vortexed and centrifuged at 15,000 rpm for 15 min at 4°C for
injection. A raloxifene control in phosphate buffer incubated
with a boiled S9 fraction was used as the negative control.

Data were presented as mean ± standard deviation.
Metabolic rates were calculated using raloxifene glucuronide
concentration divided by enzyme concentration and incubation time. Michaelis-Menten, Lineweaver-Burk, and EadieHofstee plots kinetic models were selected by comparison of
Akaike information criterion values, lower Akaike values indicating a better-fit model will be chosen. Kinetic parameters
Km, Vmax, and intrinsic clearance (Clearance) values were
obtained via nonlinear regression analysis of the MichaelisMenten equation. Two-way ANOVA was used to test the
effect of age and the intestinal segment on raloxifene glucuronidation. The raloxifene pharmacokinetic data were analyzed using WinNonlin 6.3 with the non-compartmental model. Un-paired Student’s t-test (Microsoft Excel) was used to
analyze the PK parameters at different ages.

Western Blotting
To investigate the age-related difference in glucuronidation
activity, Ugt con tent in duod enum and liver S9
fractions samples from 4-, 11-, and 28-week rats were measured using Western blot. Aliquots of S9 fraction samples were
separated on a 10% SDS-PAGE gel using electrophoresis in a
running buffer. Then, the gels were transferred to a polyvinylidene fluoride membranes and the membrane was blocked in
5% FBS in Tris-buffered saline Tween 20 overnight, followed
by incubation with Ugt1a primary antibody at 4°C overnight
in a Tris-buffered saline Tween 20 buffer at 1:1000 dilution
(Cell Signaling Technology, Inc., MA). After incubation with
primary antibodies, the membrane was allowed to return to
room temperature, rinsed with Tris-buffered saline Tween 20
3 times, and the band visualization was achieved by incubating with appropriate horseradish peroxidase-conjugated secondary antibody and chemiluminescence agents.
Densitometry analysis was conducted using a ChemiDoc
MP Imaging System from Bio-Rad laboratories.
Pharmacokinetic Study
For oral administration, raloxifene (4 mg/ml) was dissolved in
ethanol:PEG400:0.1% cellulose (1:2:7) and administered
(10 mg/kg) to rats at 4-week and 11-week (n = 5 or 6) through
oral gavage as reported previously (15). For i.v. injection,
raloxifene was administered to rats at 2 mg/kg through tail
vein. Blood samples (approximately 30–50 μl) were collected
by snipping the tails at 0, 0.25, 0.5, 1, 2, 4, 6, and 24 h. Plasma
was afforded after centrifugation (8000 rpm, 3 min) and kept
at −80°C freezer until analysis. Samples were prepared using
the protocol published by us previously (12). Total raloxifene,
Ral-6-G, and Ral-4′-G were analyzed using the published
method.

RESULTS
When raloxifene was incubated with the enzymes from different regions, Ral-6-G and Ral-4′-G were detected as the
metabolites (Fig. 1). These two glucuronides were then quantified using a validated LC-MS method published by us previously (12). The kinetics parameters for both Ral-6-G and
Ral-4′-G were more accurately modeled by MichaelisMenten in all intestinal segments and liver S9 fractions rather
than by Lineweaver-Burk and Eadie-Hofstee plots kinetics.
Glucuronidation Pattern at Different Ages
The glucuronidation pattern was evaluated by incubating
raloxifene at 5 μM with different intestinal segments and liver
S9 fractions. The results showed that Ral-6-G is the major
metabolites for all regions at all ages (Fig. 2). Additionally,
significant age- and segment-related differences in Ral-6-G
and Ral-4′-G metabolic rates were observed. In the colon,
the differences of these two metabolites were 46.7 and 50 folds
at 4 and 11 weeks, while at 28 weeks, the difference is 14.5
folds. In the duodenum, the glucuronidation pattern is similar
to that in the colon. At 4- and 11- week, the metabolic rates of
Ral-6-G were 4.9 folds of that Ral-4′-G, while at 28-week, the
ratio of these two metabolites was decreased to 3.5-fold. In the
liver, the ratio of these two metabolites were similar at all ages.
The ratios of these two metabolites in the other intestinal segments were slightly different.
Glucuronidation Kinetics
The total metabolic rates were calculated using the sum concentrations of Ral-6-G and Ral-4′-G and the kinetic parameters were listed in Table I. The results showed that in the
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Fig. 2 Raloxifene glucuronidation pattern at different ages in different intestinal segments and liver (n=3).

duodenum, the total metabolic rate increased from 4-week to
11- and 28-week (Fig. 3A; Table I). The Vmax was increased
5.9-fold from 20.09 ± 1.06 pmol/mg/min at 4-week to
118.50 ± 5.34 and 121.50 ± 7.53 pmol/mg/min at 11- and
28-week, respectively. Similarly, the Km value was also increased approximately 2-fold from 4-week to 11- and 28week (Table I) and the Clearance was increased about 2.9
and 3.5-fold from 4-week to 11- and 28-week, respectively.
When compared 28-week with 11-week, the Vmax, Km,
and Clearance did not change significantly.
In the other intestinal segments, the Vmax, Km, and
Clearance are various slightly (Fig. 3 B, C D, Table I) at
different ages. For the liver, both Vmax and Km are similar
at 4-week and 11-week but increased significantly when compared to those at 28-week. However, the liver clearance only
slightly decreased from 4-week to 11- and 28-week (Table I).
To fully evaluate the glucuronidation pattern, the Vmax,
Km, and Clearance of Ral-6-G and Ral-4′-G were calculated
using the data when raloxifene was incubated with S9 fractions from different regions. The results showed that both Ral6-G and Ral-4′-G metabolic rates were age-dependent in the
duodenum (Figs. 4 and 5, and Table II). The Vmax and Km
of these two metabolites at 4-weeks rats were significantly
Table I Kinetic parameters of total
raloxifene glucuronide (Ral-6-G +
Ral-4′-G) in different regions at different ages

Kinetics parameters

Km(μM)

Vmax(pmol/mg/min)

Clearance

lower than those at 11- and 28-weeks parameters. The Km
and Vmax of the Ral-6-G was age-dependent increased from
1.224 ± 0.330 μM to 2.033 ± 0.389 and 1.805 ± 0.529,
16.71 ± 0.97 pmol/mg/min to 94.18 ± 4.41 and 89.96 ±
6.29 pmol/mg/min in duodenum, respectively. The Km
and Vmax of the Ral-4-G were 2.1 ~ 4.9-fold lower than
Km and Vmax of the Ral-6-G, but they were also agedependent increased in the duodenum. Consistent with the
Km and Vmax results, the Clearance for Ral-6-G and Ral4′-G was significantly lower at 4-week when compared to
those at 11- and 28-week in the duodenum. In the jejunum
and ileum regions, the Vmax and Km of Ral-6-G and Ral-4′G were slightly changed at different ages, but clearance in
jejunum and ileum are higher at 4-week than those at 11and 28-week.
Ugt1 Expression in the Duodenum and the Liver
Upon observing age-related increases in duodenum glucuronidation activity, we further examined UGT protein
expression in the duodenum S9 fraction samples at different ages using Western blot. The results showed that
the Ugt1a expression in the duodenum at 11- and 28-

Regions

Ages(weeks)
4w

11w

28w

Duodenum

1.20 ± 0.27

2.44 ± 0.40*

2.048±0.48*

Jejunum
Ileum

1.41 ± 0.17
1.43 ± 0.19

2.045 ± 0.32*
2.153 ± 0.30*

2.211±0.21*
1.645±0.38

Colon
liver

1.43 ± 0.16
3.18 ± 0.19

0.658 ± 0.08*
3.514 ± 0.39

0.906±0.10*
7.145±0.66*#

Duodenum
Jejunum

20.09 ± 1.06
100.20 ± 5.93

118.5 ± 5.34*
89.17 ± 5.97

121.50±7.53*
98.22±5.02

Ileum
Colon
liver
Duodenum
Jejunum
Ileum
Colon
liver

71.31 ± 4.55
25.95 ± 1.44
178.40 ± 3.13
16.69 ± 1.75
71.27 ± 4.17
50.04 ± 6.38
18.10 ± 2.01
56.13 ± 1.98

57.31 ± 4.24*
25.23 ± 2.28
183.1 ± 8.39
48.58 ± 4.38*
43.61 ± 5.84*
26.62 ± 3.94*
36.78 ± 3.74*
52.1 ± 4.77

62.68±3.66*
19.54±0.85*#
305.5±11.25*#
59.28±7.35*
44.43±4.54*
38.11±4.45*#
21.57±1.88#
42.75±3.15*

*, p < 0.05 compared with 4 weeks; #, p < 0.05, compared with 28 weeks (t-test)
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Fig. 3 Regional Glucuronidation and clearance of Raloxifene metabolism in rat S9 fraction. The glucuronidation reaction was carried out for 60 min at 37°C with
0.125, 0.25, 0.5, 1, 2.5, 5, 10, 12.5, 25 μM raloxifene. The S9 fractions were made from duodenum (Duo), Jejunum (Jej), ileum(Ile), colon and liver used in the
study, the metabolic clearance of raloxifene to metabolite by each enzyme is given as the Vmax/Km ratio. Each column represents the mean and error bars
indicate the S.D (n=3).

week was 3.7 and 2.8 folds higher than that of 4-week
(Fig. 7). In the liver, the expression of Ugt1a was similar
at all the three ages.
Pharmacokinetics of Raloxifene at Different Ages
in Rats
Because the total clearance at 11-week is similar to that at 28week, we compared the PK profile using female F344 rats at

4- and 11-week (Fig. 6). Total raloxifene, Ral-6-G, and Ral-4′G were quantified in the plasma using the robust LC-MS
method published by us previously (12). The results showed
when raloxifene was administered through oral route, the
plasma AUC 0-t of raloxifene at 4-weeks (4456.78 ±
1328.32 nmol h/L) was about 3.6-fold higher than that at
11-week (1254.57 ± 296.07 nmol h/L, Fig. 6A, Table IV).
The absolute oral bioavailability (F%) of raloxifene was significantly higher at 4-week (75.4%) compared to that at 11-week

Fig. 4 Regional Glucuronidation and clearance of raloxifene −6-glucuronide in rat S9 fraction. The glucuronidation reaction was carried out for 60 min at 37°C
with 0.125, 0.25, 0.5, 1, 2.5, 5, 10, 12.5, 25 μM raloxifene. The S9 enzyme fraction of rat were made from duodenum (Duo), Jejunum (Jej), ileum (Ile), colon
and liver used in the study, the metabolic clearance of raloxifene to metabolite by each enzyme is given as the Vmax/Km ratio. Each column represents the mean
and error bars indicate the S.D (n=3).
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Fig. 5 Regional Glucuronidation and clearance of raloxifene −4′-glucuronide in rat S9 fraction. The glucuronidation reaction was carried out for 60 min at 37°C
with 0.125, 0.25, 0.5, 1, 2.5, 5, 10, 12.5, 25 μM raloxifene. The S9 enzyme fraction of rat were made from duodenum (Duo), Jejunum (Jej), ileum (Ile), colon
and liver used in the study, the metabolic clearance of raloxifene to metabolite by each enzyme is given as the Vmax/Km ratio. Each column represents the mean
and error bars indicate the S.D (n=3).

(19.3%). The plasma ratios of Ral-6-G vs Ral-4′-G were 1.68
and 0.04 at 4-week and 3.93 and 0.44 at 11-week, respectively
(Table IV), suggesting that metabolic rates at 4-weeks were
slower than those at 11-week. When raloxifene was administered through IV route, the terminal half-life of raloxifene was
significantly longer at 11-week (5.98 ± 1.16 h) compared to
that at 4-week (3.76 ± 0.69 h), while half-lives of Ral-6-G
and Ral-4′-G were similar at these two ages (Fig. 6B,
Table III).
Estimation of In Vivo Glucuronidation
The in vivo glucuronidation capability was estimated using the ratio of Ral-6-G/Ral and Ral-4′-G/Ral. The results
showed that the ratios of Ral-6-G/Ral were 1.68 and
3.93 at 4-week and 11-week, respectively, and the ratios of Ral-4′-G/Ral were 0.04 and 0.44 at 4-week and
11-week, respectively (Table IV). The in vivo glucuronidation estimation indicated that in vivo glucuronide exposure at 4-week is significantly lower than those at 11week, which is consistent with the results observed in
in vitro metabolism studies.

DISCUSSION
Raloxifene undergoes extensive glucuronidation in the GI
tract and the liver to afford two metabolites Ral-6-G and
Ral-4′-G (Fig. 1), where Ral-6-G is the major metabolite compared to Ral-4′-G (Fig. 2). We determined raloxifene glucuronidation in different regions using S9 fractions prepared

from rats at different ages. The results showed that in the
duodenum, the metabolic rates for both Ral-6-G and Ral4′-G were significantly lower at 4-week compared to that of
11-and 28-weeks (Fig. 3, 4, 5). The total clearance (Ral-6-G
and Ral-4′-G) was gradually decreased in the GI tract from
duodenum, jejunum, ileum, and colon at all three ages other
than 4-week of the duodenum (Fig. 3F). The clearance for
each metabolite in the GI tract and the liver was age and
region dependent (Fig. 4F, 5F). The Km values in different
regions at different ages were fluctuant (Table I and II). PK
studies showed that the oral bioavailability of raloxifene was
significantly higher at 4 weeks when compared to that at 11
weeks (Table IV, Fig. 6). In addition, raloxifene half-life was
significantly longer at 11 weeks when compared to that at 4
weeks (Table III, Fig. 6).
Age is known to affect intestinal function (16) and agedependent glucuronidation in the GI tract and the liver have
been reported in rodents and humans (17, 18). Raloxifene is
administered through oral route and undergoes glucuronidation, resulting in low oral bioavailability. In most of the clinical
trials, regardless of what age, raloxifene’s dose (i.e., 60 mg/
day) was same as that in postmenopausal women. However, it
is not clear whether raloxifene’s disposition and in vivo exposure are age dependent. In this study, we determined raloxifene’s metabolism and PK profiles at different ages in F344
rats to address these concerns. It was reported that rats are
sexually mature at 6 weeks and socially mature at around 5–
6 months (20–25 weeks) (19, 20). Therefore, we conducted the
experiments using F344 rats at the age before sexually mature
(i.e., 4 weeks old), after sexually but before socially mature (i.e.,
11 weeks old), and after socially mature (i.e., 28 weeks old) and
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0.86 ± 0.07*
3.10 ± 1.82*

45.99
27.81
13.33
35.93
33.51

11w

±
±
±
±
±

6.88*
3.55*
2.31*
1.86
2.88*
12.16 ± 2.34*
18.84 ± 2.26
45.83 ± 2.64
0.98 ± 0.12*
3.66 ± 0.41*

49.24
26.58
17.17
18.83
31.78

28w
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Fig. 6 Plasma concentration versus time profiles of raloxifene and its glucuronides after oral administration (A) and intravenous administration (B) at 4- and 11week (n = 5). Green line, 4 weeks; Blue line, 11 weeks. Raloxifene administered at 10 mg/kg by oral or 2 mg/kg by intravenous to Fisher 344 rats. Each symbol
represents the mean and the error bars indicate the S.D.

expect to determine the impact of both body and social status
on the disposition and oral bioavailability of raloxifene. A
10 mg/kg dose (human equivalent dose, 96 mg/kg) was used
in the oral PK studies, which is slightly (1.6-fold) higher than
that in human to ensure the measurement of Ral-4′-G in the
plasma.
We determined the impact of age on raloxifene oral bioavailability, which has never been reported previously, using
rats at 4- and 11-week since the total raloxifene glucuronidation clearance at 11-week is similar as that at 28-week. The
results showed that the absolute bioavailability (F%) of
Table III

raloxifene at 4-week (75.4%) was significantly higher than that
at 11-week (19.3%, Table IV, Fig. 6A). It was reported that
raloxifene PK could be affected by intestinal glucuronidation
(21), however, the impact of different intestinal segments on
raloxifene oral bioavailability is unknown. Usually, the jejunum and ileum are believed to be the major drug disposition
segments and the duodenum is treated as a breaking throw
organ. For raloxifene, we found that duodenum and colon
metabolic clearances were significantly lower at 4-week
than that at 11-week (Table I). Since colon is the last part of
the GI tract and the chance for raloxifene to be absorbed in

Pharmacokinetic parameters of raloxifene after intravenous to Fisher 344 female rats (n = 5, parameters represent mean ± SD)

Parameters

Raloxifene

Raloxifene-6-glu

Raloxifene-4′-glu

4 weeks

11 weeks

4 weeks

11 weeks

4 weeks

11 weeks

T1/2(h)

3.76 ± 0.69

5.98 ± 1.16*

4.08 ± 2.02

8.86 ± 2.50*

0.70 ± 0.20

0.72 ± 0.16

Tmax(h)
Cmax(nmol/L)
AUC0 ~ t(nmol h/L)
AUC0 ~ ∞(nmol h/L)
Vz(L/kg)
CL(L/h/kg)
MRT(h)

0.33 ± 0.12
676.0 ± 421.7
1182.23 ± 746.89
1182.23 ± 746.90
27.72 ± 13.74
4.92 ± 2.20
2.74 ± 0.32

0.25 ± 0.0
772.2 ± 360.69
1298.23 ± 462.28
1298.23 ± 462.29
27.9 ± 6.12
3.4 ± 1.19
3.68 ± 1.57

0.33 ± 0.12
362.0 ± 22.2
774.4 ± 203.8
774.4 ± 203.9
29.2 ± 12.82
5.56 ± 1.38
3.37 ± 1.52

0.40 ± 0.30
231.0 ± 7.67
766.29 ± 115.28
766.29 ± 115.29
61.2 ± 10.34*
5.02 ± 0.98
5.89 ± 0.93

0.33 ± 0.12
43.17 ± 7.31
47.06 ± 5.09
47.06 ± 5.10
89.28 ± 24.03
89.63 ± 10.86
0.90 ± 0.28

0.25 ± 0.0
18.62 ± 1.60*
21.58 ± 2.55*
21.58 ± 2.56*
198.04 ± 33.73*
193.75 ± 26.65*
0.91 ± 0.16

*, p < 0.05 compared with 4 weeks (unpaired t-test)
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Table IV Pharmacokinetic parameters of raloxifene after oral administration to Fisher 344 female rats (n = 5, parameters represent mean ± SD, F was
calculated by dividing the oral AUCs by the intravenous AUCs corrected by doses)
Parameters

Raloxifene

Raloxifene-6-glu

Raloxifene-4′-glu

4 weeks

11 weeks

4 weeks

11 weeks

4 weeks p.o.

11 weeks

T1/2(h)

10.67±3.44

54.76±29.35*

15.53±4.15

11.11±2.98

18.56±6.64

16.97±5.64

Tmax(h)
Cmax(nmol/L)
AUC0 ~ t(nmol h/L)
AUC0 ~ ∞(nmol h/L)
Vz(L/kg)
CL(L/h/kg)
MRT(h)
F(%)
In vivo glucuronidation

1.67±0.47
617.75±189.59
4456.78±1328.32
13,370.35±3984.95
12.61±4.60
0.83±0.26
7.83±1.44
75.4%

2.67±1.15
74.13±28.14*
1254.57±296.0*7
4474.85±1214.26*
363.87±42.15*
5.21±2.26*
11.14±0.93*
19.3%

0.25±0.0
2100.75±982.9
7531.83±2105.29
9264.15±2589.51
8.3±1.89
0.40±0.13
8.14±1.58

3.5±1.91
491.25±158.92*
4926.03±2006.77
6069.23±2119.21
60.48±26.11*
3.75±1.01*
8.72±0.69

2.5±0.87
23.34±13.61
186.73±61.54
250.22±82.46
376.25±166.83
14.02±2.87
18.56±6.64

3.6±1.67
51.86±32.85
554.36±340.19
765.63±381.83*
876.03±640.53
33.32±14.77*
9.4±0.76*

1.68

3.93

0.04

0.44

*, p < 0.05 compared with 4 weeks (t-test)

the colon is low it is plausible that significant amount of drug
was absorbed in the duodenum, resulting in different in vivo
exposure. This is an interesting evidence showing that duodenum disposition could dominate drug oral bioavailability. The
in vivo metabolism estimation (Table IV) confirmed that lower
metabolic rate at 4-week is associated with high raloxifene oral
bioavailability at 4-week. Age-dependent oral bioavailability
suggests that raloxifene dose should be carefully considered
when administered at different ages in clinical trials.
Another interesting finding in PK studies is age-dependent
enterohepatic recycling (EHR). In the PK study, double absorption peaks and long terminal half-life in the oral PK profiles (Fig. 6), which are two typical characters of EHR (22),
clearly demonstrated the existence of EHR. In addition, at
least Ral-6-G is a good substrate of MRP2 efflux transporter
(23), which is a key factor to facilitate EHR mediated by glucuronidation pathway (24). When compared EHR at 4- and
11-week, we found that the raloxifene half-life was significantly shorter at 4-week, suggesting that the efficiency of EHR at
4-week is lower. The possible reasons for low recycling efficiency at 4-week could be age-dependent efflux transporter
(e.g., MRP2) expression and age-dependent intestinal microbiota, which hydrolyzes raloxifene glucuronide to facilitate
raloxifene’s recycling via the glucuronidation pathway (25,
26).
In vitro metabolism study showed that the total raloxifene
glucuronidation is age-dependent but is only significant in
the duodenum (Fig. 3). Before sexually mature (i.e., 4-week),
the total glucuronidation rate is significantly lower than
those at the elder ages (i.e., 11-, 28-week). The intrinsic
clearance was gradually decreased from the duodenum to
the colon in the GI tract other than 4-week (Fig. 3F), suggesting after sexually mature, the upper part is the major
disposition segments in the GI tract. For Ral-6-G and Ral4′-G, the metabolic rates follow the same tendency (Figs. 4

and 5). For Ral-6-G, the clearance of the duodenum and
colon is lower than those of jejunum, ileum, and liver at 4week (Fig. 4F). Interestingly, when clearance of duodenum
and colon increased at 11-week (green and purple lines), the
clearance of jejunum, ileum, and liver (brown, blue, and red
lines) decreased, suggesting that these regions may have
complementary effect. From 11-week to 28-week, the clearance of the duodenum is static, while the clearance of jejunum, ileum, and liver was also static without decreasing.
The clearance of the colon was decreased from 11- to 28week somehow. For Ral-4′-G, clearance of duodenum and
colon gradually increased at different ages and a similar
complementary tendency was in the other three regions
was observed (Fig. 5F). In term of Km, all the segments were
smaller at 4-week other than the colon (Table I). These
findings suggested that UGTs in the duodenum does not
achieve mature status before sexually mature in F344 rats.
The semi-quantification analysis by Western blot showed
that the expression of Ugt1a in the duodenum was significantly lower at 4-week when compared those at 11- and 28-week
(Fig. 7). Lower Ugt1a expression at 4-week in the duodenum,
which is consistent with those reported earlier (17), is the major reason why glucuronidation at 4-week is significantly lower
than those at 11- and 28-week in duodenum (Figs. 3, 4, 5). In
the liver, where glucuronidation rates were similar at different
ages, the Ugt1a expression levels were similar (Fig. 7) at 4-,
11-, and 28-week.
The results also showed that Ral-6-G is the major metabolites for all regions at all ages when compared to Ral-4′-G
(Fig. 2). In the duodenum and colon, the ratios of these two
metabolites are different at age of 28-week with the other two
younger ages, suggesting that the relevant UGT isoforms mediated these two metabolites challenged at older age. In the
liver, the ratios of these two metabolites is stable, revealing
that the composition of the relevant UGT isoforms are stable
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in this region at young age, which could significantly increase
in vivo raloxifene exposure. In addition, raloxifene enterohepatic recycling efficiency could be lower at young age resulting
in different terminal half-life in vivo. These finding suggest that
raloxifene dose should be carefully considered in clinical studies when it is used at different ages.
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Fig. 7 Ugt1a expression in the duodenum and liver microsomes at different
ages determined by Western blot. Liver and duodenum microsomal samples
were 30 or 60 μg/well, respectively. Beta-actin was used as the loading
control (*, p < 0.05 compared to 4-week, t-test)

at different ages. In humans, Ral-6-G is mainly produced by
UGT1A1 and 1A9, while Ral-4′-G is mainly produced by
UGT1A8 and 1A10. Raloxifene metabolism with rat supersomes has never been studied, probably because of lack of rat
UGT supersomes.
Other than glucuronidation, sulfonation by SULTs and
oxidation by CYPs were also reported as metabolic pathways
for raloxifene (27, 28). In addition, the expression of SULTs
and CYPs are also age dependent (29). For example, it was
reported that the mRNA level of SULTs in the liver in rats
was increased with age after born and reached to plateau after
4 weeks (30) and the mRNA levels of the majority of CYP
isoforms in the rat liver were increased with age after born
and then either maintained the expression or decreased with
age from adulthood (29). Therefore, sulfonation and oxidation of raloxifene may also be age dependent. However, the
impact of sulfonation and oxidation on raloxifene in vivo exposure is minor. In a previous PK study, we found that the
systemic exposure of raloxifene-sulfate was significantly lower
(10–180 folds) than those of glucuronides in F344 rats (12).
Studies from other research groups revealed that raloxifene
oxidative metabolites are almost non-detectable in in vivo studies (31). Therefore, we didn’t determine the impact sulfonation and oxidation on raloxifene’s in vivo exposure at different
ages in this study.

CONCLUSION
Raloxifene glucuronidation is age dependent in the duodenum in rats probably due to unmatured UGT development
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